Ingredion (NYSE: INGR) and Tate & Lyle (LSE: TATE) jointly announced a recommended all-cash takeover on 8 June 2026, with Ingredion offering 595 pence per share for the FTSE 250 specialty-ingredients group — an equity value of about £2.7 billion ($3.6 billion) and an enterprise value of roughly £3.7 billion ($5.0 billion) (Ingredion press release; Ingredion Form 8-K, 8 June 2026). The price is a 59% premium to where Tate & Lyle shares closed on 13 May 2026, the day before press reports surfaced of a possible approach.
For Ingredion, the deal is the largest in the company’s history and a bet that combining two complementary specialty-ingredient portfolios — texturizers, sweeteners, stabilizers, and clean-label proteins — will produce $130 million of annual cost synergies by 2030. For London, it is yet another FTSE name lining up to leave: Tate & Lyle, a 165-year-old British company that once defined the country’s sugar trade, would be the latest in a long line of UK-listed mid-caps to be taken private or taken over by a foreign acquirer at a substantial premium.
The deal terms in one table
| Term | Detail |
|---|---|
| Offer price | 595 pence per Tate & Lyle share, in cash |
| Premium | ~59% to undisturbed 13 May 2026 close |
| Equity consideration | ~£2.7 billion ($3.6 billion) |
| Enterprise value | ~£3.7 billion ($5.0 billion) |
| Permitted dividends | Final dividend up to 13.2p; interim up to 6.8p — paid on top of 595p |
| Financing | Existing cash, new debt, and a fully committed bridge facility |
| Pro forma net leverage | ~3.0x net debt / adj. EBITDA at close; target 2.5x within 18 months |
| Cost synergies | $130m annual run-rate, fully realized by end-2030 |
| Structure | Court-sanctioned scheme of arrangement, Part 26 Companies Act 2006 |
| Expected close | Second half of 2027, subject to Tate & Lyle shareholder vote, court sanction, and antitrust clearances |
Why 595p — and what “undisturbed” means here
Under the UK Takeover Code, a “recommended” offer means the target board is prepared to advise shareholders to accept; “all-cash” means no Ingredion stock is being issued to Tate & Lyle holders, removing currency and dilution risk from the consideration. The 59% premium is calculated against Tate & Lyle’s undisturbed share price — the last close (13 May) before press leaks lifted the stock. From the day reports of an approach surfaced through 8 June, Tate & Lyle traded into the high 500s as arbitrage desks priced in deal certainty.
That premium is large by recent standards. Across recent UK public M&A, sponsor-led takeovers have averaged closer to 40% over an undisturbed price; large strategic deals are typically in the 30%–50% range. Ingredion paid up because the FTSE 250’s valuation gap with US peers is wide, the synergy case is concrete, and Tate & Lyle’s board had a credible standalone plan. A lower number would not have produced a recommendation.
Mechanics: why this is a scheme of arrangement, not a tender offer
UK public M&A is almost always structured one of two ways: a contractual takeover offer, or a scheme of arrangement. Ingredion chose the latter, and the choice matters.
- A scheme is a court-sanctioned reorganization under Part 26 of the UK Companies Act 2006. It needs approval from a majority in number representing 75% in value of the target shareholders voting at a court-convened meeting, plus High Court sanction. Once those conditions are met, 100% of shareholders are bound — no holdouts, no residual minority.
- A takeover offer is a direct tender to shareholders, with squeeze-out only available if the bidder hits the 90% acceptance threshold under Section 979 of the Companies Act.
For a deal of this size, certainty of 100% ownership is worth the extra weeks of court process. Ingredion needs Tate & Lyle’s whole capital structure to integrate the businesses, refinance bridge debt cleanly, and exit the London listing. A scheme delivers that with a single 75% shareholder vote rather than a months-long acceptance race.
The bargain-Britain backdrop
The Tate & Lyle deal lands in the middle of a multi-year wave of UK take-privates and foreign takeovers. The FTSE 250 trades at roughly 13× forward earnings; the S&P 500 trades north of 22× — a valuation gap that lets US strategics and global private-equity firms pay headline-grabbing premiums while still buying assets at multiples that look cheap by their own market’s standards.
Some recent comparable transactions explain the pattern. In 2024, private-equity consortium led by CVC Capital Partners agreed to take Hargreaves Lansdown private for £5.4 billion. EQT’s bid for inspections group Intertek arrived this spring at a 60% premium and a £10.6 billion enterprise value. Each headline confirms the same arithmetic: a US-listed acquirer or a globally fundraised sponsor can pay a wide premium to the UK price and still own the asset for less, on a relative-multiple basis, than it would cost in their home market.
What changes for Ingredion shareholders
Ingredion will fund the cash consideration with existing balance-sheet liquidity, a new debt issuance, and a fully committed bridge facility. Pro-forma net leverage at close is expected to land near 3.0× net debt / adjusted EBITDA — elevated for a low-cyclical specialty ingredients company but consistent with how US strategics in food and chemicals have funded comparable deals.
The path back to investment-grade leverage matters: Ingredion is targeting 2.5× within 18 months of close, which implies disciplined free-cash-flow allocation toward debt paydown rather than buybacks during 2027–2028. The synergy target — $130 million of run-rate cost savings, fully realized by 2030 — is roughly 5% of combined revenue, broadly in line with what industrial buyers underwrite when they buy companies with overlapping plant networks and shared customers.
Risks and the road to close
A scheme of arrangement is not a foregone conclusion. Three things still have to happen:
- Antitrust clearances. The combined company will be a major global supplier of starches, sweeteners, and texturizers — categories where the European Commission, UK CMA, and US FTC will all want to see whether competing customers retain a viable second source.
- Shareholder vote. The scheme requires a majority in number representing at least 75% in value of Tate & Lyle holders voting at the court meeting. Index funds will follow ISS and Glass Lewis recommendations; active holders that have been overweight Tate & Lyle on a turnaround thesis may push for more.
- Interloper risk. The UK Takeover Code does not lock the target into an exclusive process. A higher bid from a strategic — a large European food company, an Asian sweeteners producer with a US footprint — would force Ingredion to either raise its price or walk.
Ingredion shares opened roughly flat on 9 June 2026, the first US trading day after the announcement, suggesting the market is comfortable with the leverage path and synergy case. Tate & Lyle shares traded close to but slightly below the 595p offer price, the typical pattern for a recommended cash scheme: arbitrage spreads narrow toward zero as deal certainty rises, but never quite hit zero until court sanction is granted.
Bottom line
Ingredion paying 595p in cash for Tate & Lyle compresses three stories into one transaction. It is the year’s largest cross-border food-ingredients deal, a textbook scheme-of-arrangement structuring for a US buyer who wants 100% ownership and a clean delisting, and another data point in the multi-year arbitrage that lets non-UK acquirers pay headline premiums for FTSE assets that still look cheap on a relative-multiple basis. If antitrust clears, by late 2027 the London market will be one large specialty-ingredients name lighter — and the bargain-Britain ledger will tick over again.
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.